Journal of hematology最新文献_第7页

Amplification of Chromosome 1q Predicts Poor Overall Survival in Newly Diagnosed Multiple Myeloma Patients. 染色体1q扩增预测新诊断多发性骨髓瘤患者的总生存率较低。

IF 1.2

Journal of hematology Pub Date : 2023-06-01 DOI: 10.14740/jh1137

Matevz Skerget, Barbara Skopec, Samo Zver, Helena Podgornik

{"title":"Amplification of Chromosome 1q Predicts Poor Overall Survival in Newly Diagnosed Multiple Myeloma Patients.","authors":"Matevz Skerget, Barbara Skopec, Samo Zver, Helena Podgornik","doi":"10.14740/jh1137","DOIUrl":"https://doi.org/10.14740/jh1137","url":null,"abstract":"Background: Chromosome 1q copy number alterations are common in newly diagnosed patients with multiple myeloma, and in most published studies, there is no distinction made between three copies or the addition of at least four copies. The impact of these copy number alterations on patient outcome and optimal treatment is not fully understood.Methods: We retrospectively analyzed 136 transplant eligible patients with newly diagnosed multiple myeloma from our national registry, who were treated with first autologous stem cell transplantation (aHSCT) between January 1, 2018, and December 31, 2021. The primary endpoint was overall survival.Results: Patients with at least four copies of chromosome 1q had the poorest prognosis, with an overall survival of only 28.3 months. In multivariate analysis, four copies of chromosome 1q were the only statistically significant factor for overall survival.Conclusions: Despite the use of novel agents, transplantation, and maintenance therapy, patients with a gain of four copies of chromosome 1q have a very poor survival rate. Therefore, prospective studies using immunotherapy in this patient population are necessary.","PeriodicalId":15964,"journal":{"name":"Journal of hematology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/09/e8/jh-12-109.PMC10332865.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9818443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-World Data of Crizanlizumab in Sickle Cell Disease: A Single-Center Analysis. Crizanlizumab治疗镰状细胞病的真实数据:单中心分析

IF 1.2

Journal of hematology Pub Date : 2023-06-01 DOI: 10.14740/jh1127

Halle Cheplowitz, Shanna Block, Jessica Groesbeck, Stefanie Sacknoff, Anthony L Nguyen, Srila Gopal

{"title":"Real-World Data of Crizanlizumab in Sickle Cell Disease: A Single-Center Analysis.","authors":"Halle Cheplowitz, Shanna Block, Jessica Groesbeck, Stefanie Sacknoff, Anthony L Nguyen, Srila Gopal","doi":"10.14740/jh1127","DOIUrl":"https://doi.org/10.14740/jh1127","url":null,"abstract":"Background: Crizanlizumab was approved by the United States Food and Drug Administration agency in 2019 for decreasing vaso-occlusive events (VOEs) in sickle cell disease (SCD). Data regarding the use of crizanlizumab in the real-world setting are limited. Our goal was to identify patterns of crizanlizumab prescriptions in our SCD program and evaluate the benefits and identify barriers to its use in our SCD clinic.Methods: We conducted a retrospective analysis of patients who received crizanlizumab at our institution between July 2020 and January 2022. We compared acute care usage patterns before and after initiation of crizanlizumab, adherence to treatment, discontinuation and reasons for discontinuation. High utilizers of hospital-based services were defined as those with more than one visit to the emergency department (ED) per month or more than three visits to the day infusion program per month.Results: Fifteen patients received at least one dose of crizanlizumab 5 mg/kg of actual body weight during the study period. The average number of acute care visits decreased following crizanlizumab initiation but was not statistically significant (20 visits vs. 10 visits, P = 0.07). Among high users of hospital-based services, the average number of acute care visits decreased after initiation of crizanlizumab (40 vs. 16, P = 0.005). Only five patients included in this study remained on crizanlizumab 6 months after initiation.Conclusion: Our study suggests that crizanlizumab use may be helpful in decreasing acute care visits in SCD, particularly among high utilizers of hospital-based acute care services. However, the discontinuation rate in our cohort was extremely high, and further evaluation of efficacy and causes contributing to discontinuation in larger cohorts is warranted.","PeriodicalId":15964,"journal":{"name":"Journal of hematology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d3/19/jh-12-105.PMC10332863.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9818446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Importance of the Third Trimester Complete Blood Count: A Case Report on Aplastic Anemia in Pregnancy. 妊娠晚期全血细胞计数的重要性:1例妊娠再生障碍性贫血报告。

IF 1.2

Journal of hematology Pub Date : 2023-06-01 DOI: 10.14740/jh1131

Jaclyn Del Pozzo, Insaf Kouba, Theodore Goldman, Jolene Muscat

引用次数: 0

Treating Acquired Factor VIII Inhibitor and Tumor-Induced Hypoglycemia in a Case of Relapsed Diffuse Large B-Cell Lymphoma. 治疗复发性弥漫性大b细胞淋巴瘤一例获得性因子VIII抑制剂和肿瘤诱导的低血糖。

IF 1.2

Journal of hematology Pub Date : 2023-06-01 DOI: 10.14740/jh1118

Preston Baker, Joseph Norton, Nasheed Hossain

{"title":"Treating Acquired Factor VIII Inhibitor and Tumor-Induced Hypoglycemia in a Case of Relapsed Diffuse Large B-Cell Lymphoma.","authors":"Preston Baker, Joseph Norton, Nasheed Hossain","doi":"10.14740/jh1118","DOIUrl":"https://doi.org/10.14740/jh1118","url":null,"abstract":"Diffuse large B-cell lymphoma (DLCBL) is a heterogenous disease, with many phenotypic subtypes and occasional paraneoplastic syndromes being present. Herein, we describe a case of a 63-year-old woman, with relapsed/refractory DLBCL (RR-DLBCL) with artifactual hypoglycemia on laboratory testing, likely related to the mechanical effects of a new factor VIII inhibitor. We demonstrate our workup, consideration, treatment, and her clinical course. This patient did not present with a bleeding phenotype despite her aberrant laboratory results, and therefore determining her risk of bleeding to weigh against further diagnostic procedures presented a difficult decision. We utilized rotational thromboelastometry (ROTEM) to assist with clinical decision making regarding her paraneoplastic factor VIII inhibitor and the patient's bleeding risk. This led to a short course of dexamethasone. Her ROTEM improved, and an excisional biopsy was performed without any bleeding. To our knowledge, this is the only reported instance where this technology was utilized in this setting. We believe utilizing ROTEM to determine bleeding risk may be a beneficial tool for clinical practice in such additional rare cases.","PeriodicalId":15964,"journal":{"name":"Journal of hematology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fe/c7/jh-12-133.PMC10332858.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9818442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sickle Cell Trait: Is It Always Benign? 镰状细胞特征:总是良性的吗?

IF 1.2

Journal of hematology Pub Date : 2023-06-01 DOI: 10.14740/jh958

Tyiesha Sharron Brown, Rachaita Lakra, Samip Master, Poornima Ramadas

{"title":"Sickle Cell Trait: Is It Always Benign?","authors":"Tyiesha Sharron Brown, Rachaita Lakra, Samip Master, Poornima Ramadas","doi":"10.14740/jh958","DOIUrl":"https://doi.org/10.14740/jh958","url":null,"abstract":"Sickle cell disease is a well-known homozygous inherited hemoglobinopathy that causes vaso-occlusive phenomena and chronic hemolysis. Vaso-occlusion results in sickle cell crisis and can eventually lead to complications involving multiple organ systems. However, the heterozygous counterpart, sickle cell trait (SCT) has less clinical significance as these patients are generally asymptomatic. This case series examines three unrelated patients with SCT ranging from the age of 27 to 61 years, who presented with pain in multiple long bones. Hemoglobin electrophoresis confirmed a diagnosis of SCT. Radiographic images of the affected sites showed osteonecrosis (ON). Interventions included pain management and bilateral hip replacement in two of the patients. Historically, vaso-occlusive disease in patients with SCT with no evidence of hemolysis or other hallmark findings of sickle cell disease is rare. There are limited reported cases of ON in SCT patients. Clinicians should explore other hemoglobinopathies not tested on routine hemoglobin electrophoresis and alternative risk factors for ON in these patients.","PeriodicalId":15964,"journal":{"name":"Journal of hematology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/19/45/jh-12-123.PMC10332861.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9816295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Donor Cell Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation. 异基因造血干细胞移植后的供体细胞白血病。

IF 1.2

Journal of hematology Pub Date : 2023-06-01 Epub Date: 2023-06-30 DOI: 10.14740/jh1124

Ahmed Khattab, Sunita Patruni, Gina Patrus, Yazan Samhouri, Salman Fazal, John Lister

引用次数: 0

De-Novo B-Cell Prolymphocytic Leukemia. 新生b细胞前淋巴细胞白血病。

IF 1.2

Journal of hematology Pub Date : 2023-04-01 DOI: 10.14740/jh1096

Sasmith R Menakuru, Janet Roepke, Salahuddin Siddiqui

{"title":"De-Novo B-Cell Prolymphocytic Leukemia.","authors":"Sasmith R Menakuru, Janet Roepke, Salahuddin Siddiqui","doi":"10.14740/jh1096","DOIUrl":"https://doi.org/10.14740/jh1096","url":null,"abstract":"B-cell prolymphocytic leukemia (B-PLL) is a rare B-cell neoplasm that typically presents with splenomegaly, a rising white blood cell count, and may or may not have B symptoms. The diagnosis usually requires a bone marrow biopsy and aspirate with flow cytometry and cytogenetic studies. At least 55% of the lymphocytes in the peripheral blood must be prolymphocytes to be defined as B-PLL. A thorough differential diagnosis would include mantle cell lymphoma, chronic lymphocytic leukemia (CLL) with prolymphocytes, hairy cell leukemia, and splenic marginal zone lymphoma. B-PLL is managed with regimens utilized for CLL, such as ibrutinib and rituximab but is tailored for each individual. The authors report a rare case of B-PLL in a patient with no known history of CLL. The authors discuss this entity in context of the 2017 and 2022 World Health Organization (WHO) classifications, the latter of which no longer recognizes B-PLL as a distinct entity. The authors hope that this article helps practitioners with the diagnosis and treatment of B-PLL. Perhaps with better recognition, and better documentation of histopathologic features of these rare cases going forward, it may prove to be a distinct entity again in future classifications.","PeriodicalId":15964,"journal":{"name":"Journal of hematology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a1/55/jh-12-082.PMC10181324.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9468647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Acute Promyelocytic Leukemia Treatment Masking Hepatic Tuberculosis: A Management Dilemma. 急性早幼粒细胞白血病治疗掩盖肝结核:管理困境。

IF 1.2

Journal of hematology Pub Date : 2023-04-01 DOI: 10.14740/jh1109

Kimberly Boldig, Amy Kiamos, Trevanne Matthews-Hew, Reeba Omman, Walter Quan

{"title":"Acute Promyelocytic Leukemia Treatment Masking Hepatic Tuberculosis: A Management Dilemma.","authors":"Kimberly Boldig, Amy Kiamos, Trevanne Matthews-Hew, Reeba Omman, Walter Quan","doi":"10.14740/jh1109","DOIUrl":"https://doi.org/10.14740/jh1109","url":null,"abstract":"Acute promyelocytic leukemia is a form of acute myeloid leukemia (AML) that is characterized by presence of a promyelocytic leukemia-retinoic acid receptor alpha fusion. In most patients, this fusion is detected on conventional karyotype as the t(15;17)(q24.1;q21.2) translocation, but some patients have cryptic translocations with a normal karyotype. Historically, AML is associated with a poor prognosis. Treatment with all-trans retinoic acid and arsenic trioxide assures long-term survival in the majority of patients. This treatment is generally well-tolerated but may cause hepatotoxicity. This is usually identified by transaminitis but resolves after temporary cessation of treatment. Our patient's hepatotoxicity did not resolve following all-trans retinoic acid and arsenic trioxide cessation which posed a diagnostic dilemma. This prompted exploration of other possible causes of hepatotoxicity. An eventual liver biopsy identified acid-fast bacilli, confirming a diagnosis of hepatic tuberculosis. A broad differential diagnosis is imperative when investigating abnormalities in liver function, especially in chemotherapy patients when treatment cessation may cause cancer progression.","PeriodicalId":15964,"journal":{"name":"Journal of hematology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/69/5b/jh-12-100.PMC10181323.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9468644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Primary Diffuse Large B-Cell Lymphoma of the Bone. 原发性骨弥漫性大b细胞淋巴瘤。

IF 1.2

Journal of hematology Pub Date : 2023-04-01 DOI: 10.14740/jh1087

Binoy Yohannan, Adan Rios

引用次数: 0

Treatment and Response Evaluation Challenges in a Pregnant Woman With B-Cell Lymphoblastic Leukemia and Li-Fraumeni Syndrome. b细胞淋巴细胞白血病和Li-Fraumeni综合征孕妇的治疗和反应评估挑战。

IF 1.2

Journal of hematology Pub Date : 2023-04-01 DOI: 10.14740/jh1107

Bjarte Skoe Erikstein, Aymen Bushra Ahmed, Rakel Brendsdal Forthun, Friedemann Leh, Bjørn Tore Gjertsen, Håkon Reikvam

{"title":"Treatment and Response Evaluation Challenges in a Pregnant Woman With B-Cell Lymphoblastic Leukemia and Li-Fraumeni Syndrome.","authors":"Bjarte Skoe Erikstein, Aymen Bushra Ahmed, Rakel Brendsdal Forthun, Friedemann Leh, Bjørn Tore Gjertsen, Håkon Reikvam","doi":"10.14740/jh1107","DOIUrl":"https://doi.org/10.14740/jh1107","url":null,"abstract":"Li-Fraumeni syndrome (LFS) is a cancer predisposing syndrome caused by pathogenic germline TP53 gene mutations with important therapeutic and prognostic implications for many types of cancer. A small proportion of LFS patients develop B-cell lymphoblastic leukemia (B-ALL) in adult years. Standard treatment often proves inadequate, but immunotherapy has provided new treatment options. The current case report presents a pregnant woman with LFS and newly diagnosed B-ALL with hypodiploidy developed after treatment for early-onset breast cancer. We describe the treatment course, treatment-related complications and provide laboratory data crucial for evaluating and modifying treatment for this difficult clinical case. Our findings support the need for close collaboration between clinicians and experts on immunophenotyping. Through our report, we show that immunotherapy is feasible in patients with LFS and B-ALL, despite a poor initial response to induction therapy.","PeriodicalId":15964,"journal":{"name":"Journal of hematology","volume":null,"pages":null},"PeriodicalIF":1.2,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4a/5f/jh-12-092.PMC10181328.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9468643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0